Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.53 by 4.58 percent. This is a 44.14 percent increase over earnings of $1.11 per share from the same period last year. The company reported quarterly sales of $376.708 million which beat the analyst consensus estimate of $359.053 million by 4.92 percent. This is a 42.23 percent increase over sales of $264.861 million the same period last year.